Description of Medical ServiceThe proposed service is a novel form of brachytherapy for non-melanoma skin cancer (NMSC), which uses the Beta emitter radioisotope Rhenium-188. During treatment, the affected area of the skin is covered with the sterile protective foil. The Rhenium-188 is then applied in a matrix on the foil using a special applicator device. The irradiation time required to achieve the desired target dose at the defined penetration depth is calculated based on the radioactivity of the substance being applied and the surface area to be treated. After the calculated irradiation time, the matrix is removed by pulling the foil from the skin. It can be provided without anaesthesia, over a short period of time in an outpatient setting.
Description of Medical ConditionNMSC, also known as keratinocyte cancer, includes basal cell carcinoma, squamous cell carcinoma, and various other less common lesions. The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.
Reason for ApplicationNew MBS item
Medical Service TypeTherapeutic
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1070 KB)
Application Form (Word 162 KB)
Consultation SurveyConsultation Survey (PDF 690 KB)
Consultation Survey (Word 72 KB)
Consultation closes 5 November 2021
MSAC Consultation TBA – please subscribe to the MSAC Email Bulletin to be notified when consultation opens for this application
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process